Abiopharma

🔍 Leverenz Justin Martin (Director)

Company: H World Group Ltd (HTHT)

Report Date: 2026-08-15

Detailed Transactions and Holdings:

• Acquired 164,050 shares of Ordinary Shares (Direct)
  Date: 2026-08-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 164,050.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Ordinary Shares (represented by American depositary shares) (Direct)
  Date: 2026-08-15 | Code: H | shares_owned_after: 201,790.00
• Holds 0 shares of Ordinary Shares (represented by American depositary shares) (Direct)
  Date: 2026-08-15 | Code: H | nature_of_ownership: By an Irrevocable Trust | shares_owned_after: 86,900.00 | Footnotes: F2
• Sold 164,050 shares of Restricted Share Units (Derivative)
  Date: 2026-08-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 492,150.00 | transaction_form_type: 4 | Footnotes: F3, F4, F4

Footnotes:

• F1: Reflects restricted share units that vested and settled into ordinary shares.
• F2: Johann Spencer Leverenz, the son of Justin Martin Leverenz, is the beneficiary of the Irrevocable Trust, and Nancy Hu, the wife of Justin Martin Leverenz, is the trustee of the Irrevocable Trust.
• F3: Each restricted share unit represents the right to receive one ordinary share.
• F4: These restricted share units were granted on August 5, 2025 and vested on August 15, 2026. These restricted share units were previously reported on the Form 3 filed by the Reporting Person on March 16, 2026.